Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Zealand Gains as Sanofi Will Speed Up Lyxumia: Copenhagen Mover

May 2 (Bloomberg) -- Zealand Pharma A/S, the Danish drugmaker, rose the most in seven weeks in Copenhagen trading after partner Sanofi said it will step up commitment to develop diabetes treatment Lyxumia as a rival drug faces setbacks.

The Glostrup, Denmark-based drugmaker advanced 2.6 percent, the most since March 13, to 79 kroner with trading volume at 78 percent of the three-month daily average.

Lyxumia is used in combination with Paris-based Sanofi’s Lantus drug to help stimulate the production of insulin and is set to compete with Novo Nordisk A/S’s experimental medicine Tresiba. Bagsvaerd, Denmark-based Novo said yesterday it may take five more years to gain U.S. approval to sell the drug after regulators requested additional tests.

Tresiba’s delay is “really good news for us,” Sanofi Chief Executive Officer Chris Viehbacher said today on a conference call. “Priority has been assigned to a fixed-ratio combination of Lantus/Lyxumia” after the “recent competitor setback in the U.S.,” the drugmaker said in its earnings report.

To contact the reporter on this story: Christian Wienberg in Copenhagen at cwienberg@bloomberg.net

To contact the editor responsible for this story: Tasneem Brogger at tbrogger@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.